Coverage Gaps and Research Priorities
The following mechanisms have either no targeted treatments or treatments with evidence so preliminary that patients effectively have no proven options:
Critical gap — Epigenetic consolidation (Tier 2): No targeted therapy exists. This mechanism may explain why patients who successfully reduce Tier 1 drivers (e.g., antibody depletion via immunoadsorption) do not fully recover: the epigenetic landscape maintains the disease state. Until epigenetic-targeted treatments enter ME/CFS trials, this represents the largest single therapeutic blind spot.
Significant gap — Metabolic safe mode lock (Tier 1): MDC002 is the only treatment targeting this mechanism specifically. The itaconate shunt and IDO-driven tryptophan diversion have no approved pharmacological antagonists in clinical use for ME/CFS.
Important limitation on AIMM-targeted treatments: MDC002 addresses the downstream calcium toxicity cascade (AIMM), which is itself downstream of the four Tier 1 trigger-capable mechanisms (CNS energy crisis, metabolic safe mode lock, GPCR autoantibody cascade, TRPM3 channelopathy). MDC002 monotherapy is expected to benefit only the AIMM-dominant subtype (proportion unknown) characterized by: (a) sodium MRI-confirmed overload, (b) exercise-triggered PEM with delayed onset, (c) muscle-ischemic symptoms dominant over CNS symptoms. No clinical trial data for MDC 002 in ME/CFS exists as of 2026 to estimate population-level response rate. Patients whose ME/CFS is driven primarily by non-AIMM mechanisms (CNS-dominant, safe mode lock without AIMM, TRPM3 channelopathy without secondary calcium cascade) are unlikely to respond to MDC002 alone. The most realistic therapeutic approach, consistent with Wirth’s position that “severely ill patients will need multiple medications,” is combination therapy: downstream ion homeostasis restoration (MDC002) plus upstream mechanism-targeted interventions (autoantibody removal, beta-2 AR resensitization, blood volume restoration, TRPM3 restoration) (Rücker 2026).
Significant gap — TRPM3 channelopathy (Tier 1): Only two interventions listed (LDN and pregnenolone sulfate). The channelopathy affects NK cells, neurons, vascular smooth muscle, and pancreatic beta cells simultaneously; a single treatment targeting only one tissue will likely be insufficient.
Emerging gap — Neuromodulation: tVNS is the most clinically advanced non-pharmacological neuromodulation approach, but rTMS, tDCS, and photobiomodulation all lack sham-controlled ME/CFS RCTs. These are low-risk, non-invasive interventions that are under-investigated relative to their mechanistic rationale.
1 Emerging Neuroimmune Treatment Strategies
{{/* C25: Tiered neuroimmune care protocol (Tier 1, cert 0.40) */}}
Certainty: 0.40. A 4-tier protocol stratifying patients by GPCR autoantibody status + autonomic function + disease severity: Tier 1 (AAb−, mild-moderate): taVNS + 0.1 Hz SPB biofeedback + cholinergic support + pacing. Tier 2 (AAb+, moderate): T1 + immunomodulation (IVIG or IA or BC 007) + LDN. Tier 3 (AAb+, severe, MCAS+): T2 + mast cell stabilization + graded cold face immersion + S1P precursors. Tier 4 (AAb+, pan-autonomic failure, bedbound): T3 + efgartigimod or low-dose rituximab + NAD+ stack. (Blitshteyn, Doherty, and Steinman 2026)
Rationale. Stratifying by GPCR autoantibody status (the core neuroimmune biomarker) provides rational triage: autoantibody-negative patients focus on vagal enhancement and pacing; autoantibody-positive patients receive immunomodulation as a prerequisite. Testable in stepped-wedge cluster RCT across 4 clinics with primary endpoint COMPASS-31 at 6 months.
Limitations. Each intervention within each tier has independent evidence limitations. The tiering order is a proposal, not evidence-based. Cost and access barriers are substantial for Tier 2-4 interventions. No stepped-wedge implementation data exist in ME/CFS.
Falsifiable prediction: Stepped-wedge cluster RCT (4 clinics) will show COMPASS-31 reduction ≥15 points in AAb+ patients receiving Tier 2+ vs Tier 1 alone at 6 months. Falsified if between-group difference <10 points or p≥0.05.
{{/* DR13: IA + belimumab (Tier 1, cert 0.40) */}}
Certainty: 0.40. Immunoadsorption (IA) removes existing GPCR autoantibodies but benefit is transient (3-6 months). Belimumab (anti-BAFF, approved for SLE) blocks BAFF-mediated survival of autoreactive B cells, preventing rebound. The combination — IA for rapid removal + belimumab for sustained production suppression — could achieve durable autoantibody reduction. Patient selection: IA-responsive (≥30% improvement post-IA) + GPCR autoantibody-positive. Phase 1 pilot: n=10 IA+belimumab vs n=10 IA alone. (Blitshteyn, Doherty, and Steinman 2026) (Stein et al. 2025)
Warning — RESEARCH-STAGE ONLY, zero completed RCTs in ME/CFS. Belimumab is not approved for ME/CFS. Infection risk (pneumonia, sepsis) documented in SLE trials. The combination adds significant cost and monitoring burden. IA is invasive with vascular access requirements. No completed RCT of either IA+belimumab or belimumab monotherapy exists in ME/CFS. This is an entirely investigational combination based on mechanistic inference, not clinical evidence.
Falsifiable prediction. Combination group retains ≥ 80% of peak post-IA improvement at 12 months (PROMIS Fatigue); IA-alone retains ≤30%. Combination group shows sustained GPCR AAb suppression (≤50% baseline); IA-alone rebounds to ≥ 80% baseline.
{{/* DR14: Efgartigimod (Tier 2, cert 0.35) */}}
Certainty: 0.35. Efgartigimod (neonatal Fc receptor blocker) accelerates IgG catabolism, reducing total IgG and pathogenic autoantibodies by 50–70% within 2–4 weeks. Unlike IVIG (cost-prohibitive, approximately 5–10K per dose, 4–6h infusion), efgartigimod is a 1-hour IV infusion. The negative Phase 2 in unselected ME/CFS may reflect patient selection failure — no enrichment for GPCR autoantibody positivity. A re-do with pre-selection is warranted. (Blitshteyn, Doherty, and Steinman 2026)
Warning — RESEARCH-STAGE ONLY, zero completed RCTs in ME/CFS. Efgartigimod has zero completed RCTs in ME/CFS. The Phase 2 trial in unselected ME/CFS was negative; no autoantibody-enriched re-do has been conducted. Non-specific IgG reduction increases infection risk. Requires monitoring of IgG levels and infection surveillance. No ME/CFS safety data exist in autoantibody-selected patients. This speculation does not constitute a treatment recommendation — it is a research hypothesis.
Falsifiable prediction. Efgartigimod (10 mg/kg IV weekly ×4, then biweekly ×8) in GPCR AAb+ ME/CFS (n=20, open-label): reduces total IgG ≥50% at week 4; reduces GPCR AAb functional activity ≥60%; ≥40% of patients show ≥10-point PROMIS Fatigue improvement.
{{/* DR15: Low-dose rituximab (Tier 2, cert 0.30) */}}
Certainty: 0.30. RituxME (Fluge 2019) was negative in unselected patients using standard 500 mg × 2 dose which causes significant cytokine release syndrome (CRS — fever, rigors, fatigue — indistinguishable from PEM). Low-dose rituximab (200 mg × 2, as used in ITP) achieves B cell depletion with minimal CRS. If GPCR autoantibodies are the pathogenic target, partial B cell depletion (50-70%) may reduce autoantibody production without the fulminant CRS that may have confounded RituxME. Retreatment when B cells recover to ≥50% of baseline (typically 4-6 months). (Blitshteyn, Doherty, and Steinman 2026)
Warning — RESEARCH-STAGE ONLY, zero completed RCTs in ME/CFS. Low-dose rituximab has zero completed RCTs in ME/CFS. The RituxME trial (standard dose, unselected) was negative. No trial of any rituximab dose in autoantibody-enriched ME/CFS has been completed. CRS risk, though reduced at low dose, is not zero. Infection risk from B cell depletion. No ME/CFS safety data for low-dose regimen exist. Requires monitoring of B cell counts and immunoglobulin levels. This speculation does not constitute a treatment recommendation — it is a research hypothesis.
Falsifiable prediction. Low-dose rituximab (200 mg IV, days 0 and 14) in GPCR AAb+ ME/CFS (n=15, open-label): B cell depletion (CD19+ under 20 cells/µL) in ≥ 80%; CRS ≥ grade 2 in ≤10%; ≥30% show ≥30% PROMIS Fatigue improvement at 3 months.
Based on the coverage analysis above, the following research directions offer the greatest potential for therapeutic advance:
- Epigenetic modifier trials: Investigate epigenetic reprogramming agents (safe HDAC modulators, dietary compounds such as spermidine) in ME/CFS patients with confirmed epigenetic signatures
- TRPM3 agonist trials: Controlled trial of pregnenolone sulfate as a direct TRPM3 agonist, stratified by TRPM3 function assay (patch-clamp NK cell assessment)
- tVNS RCT in ME/CFS: Escalate from Long COVID feasibility data to a dedicated ME/CFS sham-controlled RCT targeting both ANS and neuroinflammatory outcomes
- rTMS with adapted protocol: Sham-controlled RCT addressing the retention challenge identified in the 2025 Corlier pilot (home-based or reduced session frequency design)
- Rapamycin biomarker-stratified trial: Enrich for mTOR-activation signature or epigenetic aging score to identify the responder subpopulation within the ~34% ITT signal. The pSer258-ATG13/total ATG13 ratio (
@spec-mTOR-tone-indexin Chapter Energy Metabolism and Mitochondrial Function, Section The Biogenesis Trap: ME/CFS Cells Waste Energy on Dysfunctional Mitochondrial Production) is the mechanistically most proximal candidate enrichment biomarker — it measures mTORC1 activity directly at the autophagy gate rather than through distant readouts (e.g., pS6K) or non-specific proxies (epigenetic clocks). - Combination Tier 1 targeting: Assess whether simultaneous targeting of two Tier 1 mechanisms (e.g., immunoadsorption + LDN for GPCR + TRPM3) produces additive benefit
- Pharmacodiagnostic matrix construction and retrospective validation: Build the full medication × hypothesis response matrix (pharmacodiagnostic matrix) and validate retroactively against patients with confirmed mechanisms (GPCR autoantibody-positive, TRPM3-validated). If the matrix correctly identifies the known mechanism from medication histories, the constraint-satisfaction approach is supported. This requires no new prospective trials — only systematic chart review at ME/CFS specialty centers with detailed medication records